£139.74
0.27% yesterday
London, Nov 28, 05:44 pm CET
ISIN
GB0009895292
Symbol
AZN

AstraZeneca Stock price

£139.74
+15.68 12.64% 1M
+36.60 35.49% 6M
+37.28 36.38% YTD
+36.05 34.76% 1Y
+36.07 34.80% 3Y
+70.14 100.78% 5Y
+106.66 322.48% 10Y
+127.42 1,034.63% 20Y
London, Closing price Fri, Nov 28 2025
-0.38 0.27%
ISIN
GB0009895292
Symbol
AZN
Industry

New AI Insights on AstraZeneca Insights AI Insights on AstraZeneca

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
£217.2b
Enterprise Value
£235.7b
Net debt
£18.5b
Cash
£6.2b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
30.7 | 19.8
P/S
4.9 | 4.8
EV/Sales
5.4 | 5.2
EV/FCF
32.6
P/B
6.3
Dividends
DPS
£2.46
Yield 1Y | 5Y
1.8% | 2.5%
Growth 1Y | 5Y
7.8% | 2.4%
Payout 1Y | 3Y
72.2% | 90.6%
Increased
1 Year
Financials (TTM | estimate)
Revenue
£43.9b | £45.2b
EBITDA
£13.8b | £16.3b
EBIT
£10.7b | £14.2b
Net Income
£7.1b | £10.9b
Free Cash Flow
£7.2b
Growth (TTM | estimate)
Revenue
13.5% | 10.8%
EBITDA
20.9% | 30.1%
EBIT
26.1% | 48.5%
Net Income
44.7% | 105.9%
Free Cash Flow
41.6%
Margin (TTM | estimate)
Gross
81.9%
EBITDA
31.3% | 35.9%
EBIT
24.3%
Net
16.2% | 24.2%
Free Cash Flow
16.5%
Financial Health
Equity Ratio
39.2%
Return on Equity
17.3%
ROCE
17.6%
ROIC
14.8%
Debt/Equity
0.7
More
EPS
£4.6
FCF per Share
£4.7
Short interest
-
Employees
94k
Rev per Employee
£430.0k
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

28x Buy
85%
4x Hold
12%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

Buy
85%
Hold
12%
Sell
3%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
43,894 43,894
14% 14%
100%
- Direct Costs 7,946 7,946
15% 15%
18%
35,948 35,948
13% 13%
82%
- Selling and Administrative Expenses 11,959 11,959
5% 5%
27%
- Research and Development Expense 10,318 10,318
18% 18%
24%
13,754 13,754
21% 21%
31%
- Depreciation and Amortization 3,069 3,069
6% 6%
7%
EBIT (Operating Income) EBIT 10,685 10,685
26% 26%
24%
Net Profit 7,098 7,098
45% 45%
16%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Neutral
CNBC
3 days ago
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price.
Neutral
PRNewsWire
6 days ago
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an update and advancement of its global strategic collaboration with AstraZeneca, originally establishe...
Positive
The Motley Fool
8 days ago
The pharmaceutical giant is plowing billions of dollars into expanding its drug-making capacity. It has ambitious plans for two facilities in Maryland.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today